aiwiki.page
English
Health / Drugs / methenamine-hippurate

Methenamine hippurate

Methenamine hippurate is a urinary antiseptic used to prevent recurrent urinary tract infections through the release of formaldehyde in acidic urine.

15 keywords1 linked from2 not yet writtenWritten by AI
AntisepticUrinary tract in…AntibioticKidneypHAntibiotic Resis…SepsisRandomized Contr…Methenamin…

Methenamine hippurate is an oral urinary antiseptic used for the prevention or suppression of recurrent urinary tract infections (UTIs). It is the hippuric acid salt of methenamine, also known as hexamine. In acidic urine, methenamine breaks down to release formaldehyde, which has antibacterial activity. Its principal role is prevention rather than treatment of an acute infection, and it provides an alternative to continuous low-dose antibiotics for some populations with recurrent UTIs.

Composition and mechanism

Methenamine hippurate combines methenamine with hippuric acid. After oral absorption, methenamine is excreted into the urine through the kidneys. Its antibacterial activity depends on its chemical breakdown in an acidic environment, rather than on a conventional antibiotic mechanism directed at a specific bacterial target.

The breakdown product, formaldehyde, reacts with microbial proteins and other cellular components. The rate of its formation depends strongly on urinary pH: increasingly alkaline urine reduces formaldehyde production and therefore reduces antibacterial activity. Hippuric acid contributes to the preparation’s acidic properties, but does not guarantee sufficiently acidic urine under all conditions.

This mechanism differs from those of antibiotics that inhibit bacterial cell-wall synthesis, protein synthesis, or other defined processes. Conventional target-specific antibiotic resistance is therefore less directly relevant to methenamine. Nevertheless, clinical effectiveness still depends on urinary conditions, drug exposure, and the characteristics of the urinary tract.

Clinical role

Methenamine hippurate is used chiefly as longer-term prophylaxis against recurrent UTIs. Product indications and prescribing restrictions vary by country. Some product labels describe its use for suppressive or prophylactic treatment after an existing infection has been eradicated by an appropriate antimicrobial.

It is not an equivalent substitute for antibiotic treatment of an acute symptomatic UTI. Its urinary action also makes it unsuitable as sole treatment for infection of kidney tissue or systemic infection, including sepsis.

Evidence is strongest for prevention in adult women with recurrent UTIs. Its effectiveness is less clearly established in several other settings, including patients with substantial urinary tract abnormalities, impaired bladder emptying caused by neurological disease, or long-term urinary catheters. Findings from one population cannot automatically be extended to these groups.

Evidence for effectiveness

Older studies of methenamine varied substantially in participant characteristics, treatment schedules, and definitions of infection, limiting firm conclusions.

A major subsequent study was the ALTAR trial, published in 2022. This open-label randomized controlled trial compared methenamine hippurate with daily low-dose antibiotic prophylaxis in women with recurrent UTIs over 12 months. It was designed as a noninferiority trial, assessing whether methenamine’s effectiveness remained within a prespecified acceptable margin relative to antibiotics.

During treatment, the incidence of symptomatic, antibiotic-treated UTIs was 1.38 episodes per person-year with methenamine and 0.89 with antibiotics. The difference met the trial’s predefined noninferiority criterion. This result does not mean the treatments produced identical outcomes: the methenamine group experienced more episodes, but the difference was within the margin established before analysis.

The study supports methenamine as an antibiotic-sparing preventive option in the population examined. Its open-label design and participant selection remain important when interpreting its findings. Reducing continuous antibiotic exposure is relevant to antimicrobial stewardship, although breakthrough infections can still require antibiotics.

Adverse effects, contraindications, and interactions

Reported adverse effects include gastrointestinal upset, nausea, painful urination, and skin rash. Excessive exposure can cause bladder irritation and blood in the urine.

Renal impairment, severe hepatic impairment, and severe dehydration are important restrictions in product information, although the wording and renal-function thresholds differ between jurisdictions. Renal excretion is central to both urinary drug delivery and safe use.

Two interactions are particularly relevant:

  • Urinary alkalinizing agents, including some citrate-containing preparations, can reduce effectiveness by raising urinary pH.
  • Sulfonamide antibiotics can interact with formaldehyde in urine and produce insoluble precipitates; product information generally prohibits concurrent use.

Evidence during pregnancy is more limited than evidence in nonpregnant adult women, and product labeling contains pregnancy-related cautions. Long-term effectiveness and safety in underrepresented patient groups remain less well characterized than in the populations studied in preventive trials.